Two mRNA Cancer Vaccines Advance to Next Stage of Clinical Trials

Source: NBIC+, August 2023

A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.

Two personalized messenger RNA (mRNA) cancer vaccines, using the same technology as COVID-19 vaccines, are moving forward to the next stage of clinical trials after researchers reported promising results in earlier studies.

Modern and Merck recently announced the start of a Phase III trial testing an experimental melanoma vaccine dubbed V940 (mRNA-4157), while BioNTech’s pancreatic cancer vaccine, autogene cevumeran (BNT122), is entering a Phase II trial.

Read more: https://statnano.com/news/72813/Two-mRNA-Cancer-Vaccines-Advance-to-Next-Stage-of-Clinical-Trials#ixzz8KQgjWaCm
READ THE ORIGINAL FULL ARTICLE